top of page
Search
Amit Roy

NOVN.VX: Entresto approved and priced high, but penetration may not be maximal


Entresto was approved last night for heart failure...

with what appears to be a wide label, and is being set at a high price. However guidance may imply a low penetration, and we discuss the concerns that some cardiologists may have

Focus Research
Recent Reseacrh
Archive
Search By Tags
Follow Us on:
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page